JP2011509287A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509287A5 JP2011509287A5 JP2010541885A JP2010541885A JP2011509287A5 JP 2011509287 A5 JP2011509287 A5 JP 2011509287A5 JP 2010541885 A JP2010541885 A JP 2010541885A JP 2010541885 A JP2010541885 A JP 2010541885A JP 2011509287 A5 JP2011509287 A5 JP 2011509287A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- peptide
- polysaccharide
- oil
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 235000018102 proteins Nutrition 0.000 claims 26
- 102000004169 proteins and genes Human genes 0.000 claims 26
- 108090000623 proteins and genes Proteins 0.000 claims 26
- 150000004676 glycans Chemical class 0.000 claims 20
- 229920001282 polysaccharide Polymers 0.000 claims 20
- 239000005017 polysaccharide Substances 0.000 claims 20
- 239000003921 oil Substances 0.000 claims 18
- 235000019198 oils Nutrition 0.000 claims 18
- 239000002105 nanoparticle Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000000377 silicon dioxide Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 101710172711 Structural protein Proteins 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 238000002844 melting Methods 0.000 claims 4
- 230000008018 melting Effects 0.000 claims 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims 4
- 230000005661 hydrophobic surface Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 102000055006 Calcitonin Human genes 0.000 claims 2
- 108060001064 Calcitonin Proteins 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 102000016911 Deoxyribonucleases Human genes 0.000 claims 2
- 108010053770 Deoxyribonucleases Proteins 0.000 claims 2
- 102000016942 Elastin Human genes 0.000 claims 2
- 108010014258 Elastin Proteins 0.000 claims 2
- 108010049003 Fibrinogen Proteins 0.000 claims 2
- 102000008946 Fibrinogen Human genes 0.000 claims 2
- 102000018997 Growth Hormone Human genes 0.000 claims 2
- 108010051696 Growth Hormone Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 108090000467 Interferon-beta Proteins 0.000 claims 2
- 102000003996 Interferon-beta Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 102000011782 Keratins Human genes 0.000 claims 2
- 108010076876 Keratins Proteins 0.000 claims 2
- 102000006382 Ribonucleases Human genes 0.000 claims 2
- 108010083644 Ribonucleases Proteins 0.000 claims 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 2
- 229960004015 calcitonin Drugs 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 229920002549 elastin Polymers 0.000 claims 2
- 230000010437 erythropoiesis Effects 0.000 claims 2
- 229940012952 fibrinogen Drugs 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 229960001388 interferon-beta Drugs 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 239000013618 particulate matter Substances 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims 1
- 229920000310 Alpha glucan Polymers 0.000 claims 1
- 229920000945 Amylopectin Polymers 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 229920002498 Beta-glucan Polymers 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 229920002527 Glycogen Polymers 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 238000007580 dry-mixing Methods 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 235000014304 histidine Nutrition 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 claims 1
- 239000011236 particulate material Substances 0.000 claims 1
- 239000000813 peptide hormone Substances 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL188647 | 2008-01-08 | ||
| IL188647A IL188647A0 (en) | 2008-01-08 | 2008-01-08 | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
| US8029508P | 2008-07-14 | 2008-07-14 | |
| US61/080,295 | 2008-07-14 | ||
| PCT/IL2009/000036 WO2009087633A2 (en) | 2008-01-08 | 2009-01-08 | Methods and compositions for oral administration of protein and peptide therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011509287A JP2011509287A (ja) | 2011-03-24 |
| JP2011509287A5 true JP2011509287A5 (enExample) | 2012-03-01 |
| JP5432183B2 JP5432183B2 (ja) | 2014-03-05 |
Family
ID=40326402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010541885A Expired - Fee Related JP5432183B2 (ja) | 2008-01-08 | 2009-01-08 | タンパク質およびペプチドの治療薬の経口投与に関する方法および組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20100278922A1 (enExample) |
| EP (2) | EP2254590B1 (enExample) |
| JP (1) | JP5432183B2 (enExample) |
| KR (1) | KR101588066B1 (enExample) |
| AU (2) | AU2009203530B2 (enExample) |
| BR (1) | BRPI0906866A2 (enExample) |
| CA (2) | CA2711554C (enExample) |
| DK (2) | DK2231123T3 (enExample) |
| EA (1) | EA018461B1 (enExample) |
| ES (2) | ES2397061T3 (enExample) |
| IL (3) | IL188647A0 (enExample) |
| MX (1) | MX2010007462A (enExample) |
| NZ (1) | NZ586374A (enExample) |
| WO (2) | WO2009087634A2 (enExample) |
| ZA (1) | ZA201004480B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2521295Y2 (ja) | 1991-11-13 | 1996-12-25 | シーケーディ株式会社 | 流体混合器 |
| IL188647A0 (en) * | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
| US9060932B2 (en) | 2009-07-09 | 2015-06-23 | Oshadi Drug Administration Ltd. | Matrix carrier compositions, methods and uses |
| KR101875155B1 (ko) * | 2011-05-02 | 2018-07-09 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
| US9603907B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Dry powder formulations of dNase I |
| WO2014031837A1 (en) * | 2012-08-22 | 2014-02-27 | The Regents Of The University Of California | Compositions and methods for enhancing sialic acid levels in tissue |
| EP2919903B1 (en) | 2012-11-14 | 2020-07-22 | W.R. Grace & CO. - CONN. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
| CA2899220A1 (en) * | 2013-01-29 | 2014-08-07 | Oshadi Drug Administration Ltd. | Pharmaceutical compositions for oral treatment of diabetes |
| ES2502691B1 (es) * | 2013-09-25 | 2015-07-07 | Sani-Red, S.L. | Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos |
| EP3065717A1 (en) | 2013-11-04 | 2016-09-14 | Biopharmx, Inc. | Dosage form comprising an active ingredient and a plurality of solid porous microcarriers |
| US9168211B2 (en) * | 2014-03-28 | 2015-10-27 | Johnson & Johnson Consumer Inc. | Method of making an anhydrous, pigmented composition |
| KR102418550B1 (ko) * | 2015-11-03 | 2022-07-06 | 삼성전자주식회사 | 포토 레지스트 패턴 형성 방법 및 이를 이용한 반도체 장치 제조 방법 |
| WO2017141262A1 (en) * | 2016-02-19 | 2017-08-24 | Indian Institute Of Technology, Bombay | Orally administrable pharmaceutical preparation containing protein |
| EP3485899A4 (en) * | 2017-09-25 | 2020-05-20 | Georgy Georgievich Chumburidze | THERMOSTABLE COMPOSITION HAVING ANTIVIRAL AND ANTIBACTERIAL ACTION, AND USE THEREOF |
| IT201800007947A1 (it) * | 2018-08-07 | 2020-02-07 | Vetagro Int Srl | Metodo per preparare una composizione di aminoacidi per consentire la corrispondenza dei singoli fabbisogni di amminoacidi ad un soggetto in base all'età, al genere, all'attività fisica e alla genetica |
| EA202192793A1 (ru) | 2019-04-11 | 2022-01-12 | Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи | Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью |
| WO2021053246A1 (en) * | 2019-09-20 | 2021-03-25 | University College Dublin | Oral delivery system |
| DK3937983T3 (da) | 2019-12-17 | 2025-05-05 | 9286 3620 Quebec Inc | Oral afliveringssystemer baserede på in situ-dannende protein/polysakkaridkoacervater |
| WO2021155042A1 (en) | 2020-01-28 | 2021-08-05 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer |
| AU2021310264A1 (en) | 2020-07-15 | 2023-02-09 | Schabar Research Associates Llc | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
| US20240315972A1 (en) | 2021-07-12 | 2024-09-26 | Zidkiyahu Simenhaus | Protein containing bio-active compositions comprising cellulose microparticle carriers |
| CN119630685A (zh) | 2022-06-13 | 2025-03-14 | B.A.I.实验室有限责任公司 | 结合白介素-13的环状寡肽及其使用方法 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3252859A (en) | 1962-10-24 | 1966-05-24 | Masti Kure Company Inc | Colloidal silica-oil composition and method of using same |
| US6551576B1 (en) * | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
| ES2027518A6 (es) | 1990-12-18 | 1992-06-01 | Andromaco Lab | Procedimiento para la preparacion de nuevas asociaciones no covalentes polisacarido-proteina con actividad farmacologica. |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5260002A (en) | 1991-12-23 | 1993-11-09 | Vanderbilt University | Method and apparatus for producing uniform polymeric spheres |
| US7083572B2 (en) | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
| US20040018236A1 (en) * | 1995-05-08 | 2004-01-29 | Robert Gurny | Nanoparticles for oral administration of pharmaceutical agents of low solubility |
| ES2093562B1 (es) | 1995-05-26 | 1997-07-01 | Univ Santiago Compostela | Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. |
| US5874105A (en) | 1996-01-31 | 1999-02-23 | Collaborative Laboratories, Inc. | Lipid vesicles formed with alkylammonium fatty acid salts |
| US6071535A (en) * | 1996-01-31 | 2000-06-06 | Collaborative Laboratories, Inc. | Lipid vesicles formed with alkylammonium fatty acid salts |
| US6322765B1 (en) * | 1996-02-15 | 2001-11-27 | Wacker-Chemie Gmbh | Process for preparing silicon dioxide |
| US6120751A (en) * | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US20020039594A1 (en) * | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| FR2767718B1 (fr) * | 1997-08-28 | 1999-10-22 | Oreal | Emulsion eau-dans-huile comprenant de la silice pyrogenee et un alkylether de polysaccharide |
| US6638621B2 (en) | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
| ATE246039T1 (de) * | 1997-09-09 | 2003-08-15 | Select Release L C | Beschichtete teilchen, methode zu ihrer herstellung und verwendung |
| FR2773804B1 (fr) * | 1998-01-19 | 2000-02-18 | Sanofi Sa | Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant |
| US6656922B2 (en) * | 1998-05-28 | 2003-12-02 | Mediplex Corporation, Korea | Oral delivery of macromolecules |
| EP1169024B1 (en) | 1999-03-31 | 2005-12-21 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
| US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| US7195780B2 (en) * | 2002-10-21 | 2007-03-27 | University Of Florida | Nanoparticle delivery system |
| DE10001172A1 (de) * | 2000-01-13 | 2001-07-26 | Max Planck Gesellschaft | Templatieren von Feststoffpartikeln mit Polymermultischichten |
| JP4631119B2 (ja) * | 2000-01-28 | 2011-02-16 | Ｊｓｒ株式会社 | 疎水化コロイダルシリカの製造方法 |
| US7067116B1 (en) | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
| US6548264B1 (en) * | 2000-05-17 | 2003-04-15 | University Of Florida | Coated nanoparticles |
| EP1299348B1 (en) * | 2000-06-29 | 2008-04-09 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| ATE320267T1 (de) * | 2000-08-11 | 2006-04-15 | Lohmann Animal Health Gmbh | W/o emulsion adjuvanszuzammensetzungen für impstoffen |
| US20020150621A1 (en) * | 2000-10-16 | 2002-10-17 | Kohane Daniel S. | Lipid-protein-sugar particles for drug delivery |
| FR2819720B1 (fr) * | 2001-01-22 | 2004-03-12 | Fournier Lab Sa | Nouveaux comprimes de fenofibrate |
| US6698247B2 (en) * | 2001-05-04 | 2004-03-02 | Corning Incorporated | Method and feedstock for making silica by flame combustion |
| US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| WO2003055469A1 (en) * | 2001-12-21 | 2003-07-10 | Celator Technologies Inc. | Improved polymer-lipid delivery vehicles |
| EP1458361A4 (en) * | 2001-11-20 | 2007-04-25 | Advanced Inhalation Res Inc | COMPOSITIONS FOR DISTRIBUTING PRODUCTS WITH LASTING EFFECT |
| US20030235619A1 (en) * | 2001-12-21 | 2003-12-25 | Christine Allen | Polymer-lipid delivery vehicles |
| US20030198666A1 (en) * | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US6824790B2 (en) * | 2002-01-09 | 2004-11-30 | Enzrel Inc. | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds |
| EP1472351B1 (en) | 2002-02-07 | 2007-06-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Amino acid sequences capable of facilitating penetration across a biological barrier |
| US7244498B2 (en) | 2002-06-12 | 2007-07-17 | Tda Research, Inc. | Nanoparticles modified with multiple organic acids |
| US7090868B2 (en) | 2002-09-13 | 2006-08-15 | University Of Florida | Materials and methods for drug delivery and uptake |
| ES2465496T3 (es) | 2003-01-06 | 2014-06-05 | Emisphere Technologies, Inc. | Terapia de insulina oral nocturna |
| US20040242729A1 (en) * | 2003-05-30 | 2004-12-02 | 3M Innovative Properties Company | Stabilized particle dispersions containing surface-modified inorganic nanoparticles |
| WO2005094785A2 (en) | 2003-09-17 | 2005-10-13 | Chiasma, Ltd. | Compositions capable of facilitating penetration across a biological barrier |
| EA200600877A1 (ru) * | 2003-10-31 | 2006-12-29 | Тева Фармасьютикал Индастриз, Лтд. | Наночастицы для доставки лекарств |
| KR100638041B1 (ko) * | 2003-12-24 | 2006-10-23 | 주식회사 삼양사 | 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법 |
| US20050232981A1 (en) | 2004-04-15 | 2005-10-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
| US7288134B2 (en) | 2004-09-10 | 2007-10-30 | International Business Machines Corporation | Dumbbell-like nanoparticles and a process of forming the same |
| US7282194B2 (en) | 2004-10-05 | 2007-10-16 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US20060083781A1 (en) | 2004-10-14 | 2006-04-20 | Shastri V P | Functionalized solid lipid nanoparticles and methods of making and using same |
| WO2006062506A1 (en) | 2004-12-03 | 2006-06-15 | Enzrel, Inc. | Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds |
| NZ565663A (en) | 2005-08-09 | 2011-03-31 | Univ Sunderland | The use of hydrophobic silica particles in detecting and identifying fingerprints |
| US8715739B2 (en) | 2005-10-24 | 2014-05-06 | Purdue Research Foundation | Polymer coated microparticles |
| US20070104778A1 (en) * | 2005-11-07 | 2007-05-10 | Hongxia Zeng | Controlled-release emulsion compositions |
| WO2008048288A2 (en) * | 2005-11-09 | 2008-04-24 | Montana State University | Novel nanoparticles and use thereof |
| EP1957113A4 (en) * | 2005-11-21 | 2011-11-09 | Medivas Llc | POLYMER PARTICLES FOR THE OUTPUT OF MACROMOLECULES AND METHOD OF APPLICATION THEREFOR |
| US20070184076A1 (en) * | 2006-02-07 | 2007-08-09 | Unger Evan C | Liquid-filled nanodroplets for anti-cancer therapy |
| AU2007238114B2 (en) * | 2006-04-12 | 2010-10-14 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| IL188647A0 (en) | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
| US9060932B2 (en) * | 2009-07-09 | 2015-06-23 | Oshadi Drug Administration Ltd. | Matrix carrier compositions, methods and uses |
-
2008
- 2008-01-08 IL IL188647A patent/IL188647A0/en unknown
-
2009
- 2009-01-08 MX MX2010007462A patent/MX2010007462A/es active IP Right Grant
- 2009-01-08 ES ES09700655T patent/ES2397061T3/es active Active
- 2009-01-08 CA CA2711554A patent/CA2711554C/en not_active Expired - Fee Related
- 2009-01-08 EP EP09700655A patent/EP2254590B1/en not_active Not-in-force
- 2009-01-08 DK DK09701269.4T patent/DK2231123T3/da active
- 2009-01-08 CA CA2711556A patent/CA2711556A1/en not_active Abandoned
- 2009-01-08 BR BRPI0906866-0A patent/BRPI0906866A2/pt not_active Application Discontinuation
- 2009-01-08 EP EP09701269A patent/EP2231123B1/en not_active Not-in-force
- 2009-01-08 KR KR1020107016634A patent/KR101588066B1/ko not_active Expired - Fee Related
- 2009-01-08 AU AU2009203530A patent/AU2009203530B2/en not_active Ceased
- 2009-01-08 EA EA201070827A patent/EA018461B1/ru not_active IP Right Cessation
- 2009-01-08 WO PCT/IL2009/000037 patent/WO2009087634A2/en not_active Ceased
- 2009-01-08 DK DK09700655.5T patent/DK2254590T3/da active
- 2009-01-08 ES ES09701269T patent/ES2398015T3/es active Active
- 2009-01-08 US US12/811,859 patent/US20100278922A1/en not_active Abandoned
- 2009-01-08 AU AU2009203529A patent/AU2009203529B2/en not_active Ceased
- 2009-01-08 WO PCT/IL2009/000036 patent/WO2009087633A2/en not_active Ceased
- 2009-01-08 JP JP2010541885A patent/JP5432183B2/ja not_active Expired - Fee Related
- 2009-01-08 NZ NZ586374A patent/NZ586374A/en not_active IP Right Cessation
- 2009-01-08 US US12/811,871 patent/US8936786B2/en not_active Expired - Fee Related
-
2010
- 2010-06-24 ZA ZA2010/04480A patent/ZA201004480B/en unknown
- 2010-07-06 IL IL206835A patent/IL206835A/en not_active IP Right Cessation
- 2010-07-06 IL IL206834A patent/IL206834A/en not_active IP Right Cessation
-
2014
- 2014-12-09 US US14/565,416 patent/US9949924B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011509287A5 (enExample) | ||
| Rodrigues et al. | Recent applications of starch derivatives in nanodrug delivery | |
| Narayanan et al. | Poly-(ethylene glycol) modified gelatin nanoparticles for sustained delivery of the anti-inflammatory drug Ibuprofen-Sodium: An in vitro and in vivo analysis | |
| TW553746B (en) | Powdery nasal composition | |
| JP5581227B2 (ja) | 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤 | |
| KR20110028631A (ko) | 표면 피복 미립자의 의약 조성물 | |
| KR20180129990A (ko) | 골수종의 치료 | |
| JP2012531442A5 (enExample) | ||
| JP2011519867A5 (enExample) | ||
| JP2002348234A (ja) | 薬物封入無機物微粒子、その製造法及び薬物封入無機物微粒子製剤 | |
| CN1556712A (zh) | 含dds化合物的药用组合物 | |
| KR20120084303A (ko) | 약물 함유 미립자를 포함하는 의약 조성물 및 그 제조 방법 | |
| CN104027808B (zh) | 一种抗脉管性疾病及抗肿瘤的药物组合物及其应用 | |
| AU2021308083A1 (en) | Preparations and compositions comprising polymer combination preparations | |
| KR20220134781A (ko) | 천연 중합체에 기반한 패치 제품 | |
| EP3678706A1 (en) | Albumin-modified nanoparticles carrying a targeting ligand | |
| CN102688200A (zh) | 植物类抗癌靶向纳米制剂及其制备方法 | |
| Ngwuluka et al. | Natural polymers in micro-and nanoencapsulation for therapeutic and diagnostic applications: part II-polysaccharides and proteins | |
| CN104288093A (zh) | 纳米药物透皮制剂在肿瘤中的应用 | |
| JPH10513202A (ja) | キトサン薬物送達システム | |
| CN112675312B (zh) | 一种脑靶向纳米递释系统及其制备方法 | |
| CN103976958B (zh) | 一种金纳米颗粒在制备抗凝血剂或抗血小板剂中的应用 | |
| CN107126564A (zh) | 一种白蛋白结合型索拉非尼纳米制剂及其制备方法 | |
| US11793758B2 (en) | Formulations of biological polymers for oral administration | |
| CN115400115A (zh) | 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途 |